search button

Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules

  • Authors:
    • Lingying Yu
    • Lizhen Ma
    • Qiaofeng Tu
    • Yi Zhang
    • Yueming Chen
    • Daojun Yu
    • Shaoyu Yang

  • View Affiliations

  • Published online on: April 15, 2015     https://doi.org/10.3892/ol.2015.3119
  • Pages: 2633-2638
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the prevalence of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) patients from eastern coastal China and to determine whether it is correlated with the clinicopathological features of PTCs with or without current Hashimoto thyroiditis (HT). The BRAF V600E mutation status was analyzed in 206 thyroid nodules of 154 patients undergoing thyroidectomy using polymerase chain reaction and bi‑directional sequencing. Multivariate analysis was performed to investigate the association of the BRAF V600E mutation with clinicopathological features. Thyroid nodules were classified as PTC, nodular goiter (NG), adenomatoid nodule, adenoma and HT. The BRAF V600E mutation was observed in 61.5% of PTCs analyzed; it was also detected in one normal tissue adjacent to PTC and one NG. One patient exhibited double mutations in the BRAF gene; the BRAF V600E mutation in the PTC lesion and the BRAF K601E mutation in the contralateral NG lesion. Patients harboring the BRAF V600E mutation had higher thyroid stimulating hormone levels (2.453±1.464 vs. 1.966±1.296 mIU/l), a reduced occurrence of papillary thyroid microcarcinoma (55.0 vs. 88%), and a higher occurrence of lymph node metastasis (LNM; 42.5 vs. 16.0%) compared with those with wild‑type BRAF (all P<0.05). Binary logistic regression analysis revealed that the BRAF V600E mutation was associated with LNM of PTC (hazard ratio, 5.051; 95% confidence interval, 1.068‑23.893; P=0.041). Conversely, no association was identified between the BRAF V600E mutation and HT (38.5 vs. 67.3%, χ2=3.656, P=0.056). Thus, in regional PTCs, the BRAF V600E mutation was prevalent, suggesting that it may be an early and phenotypically defining molecular event in PTC, and may represent an independent factor that predicts LNM.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 9 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yu L, Ma L, Tu Q, Zhang Y, Chen Y, Yu D and Yang S: Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules. Oncol Lett 9: 2633-2638, 2015
APA
Yu, L., Ma, L., Tu, Q., Zhang, Y., Chen, Y., Yu, D., & Yang, S. (2015). Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules. Oncology Letters, 9, 2633-2638. https://doi.org/10.3892/ol.2015.3119
MLA
Yu, L., Ma, L., Tu, Q., Zhang, Y., Chen, Y., Yu, D., Yang, S."Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules". Oncology Letters 9.6 (2015): 2633-2638.
Chicago
Yu, L., Ma, L., Tu, Q., Zhang, Y., Chen, Y., Yu, D., Yang, S."Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules". Oncology Letters 9, no. 6 (2015): 2633-2638. https://doi.org/10.3892/ol.2015.3119